# US 2026/0092061 A1 · Compounds for targeted protein degradation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092061 A1
- Document ID: US20260092061A1
- Status: Published application
- Kind: A1
- Application number: 19/110,659
- Filed: 2023-09-13
- Published: 2026-04-02
- Earliest claimed: 2022-09-13
- Applicants: Amphista Therapeutics Limited
- Inventors: David MCGARRY; Gregor MEIER; James OSBORNE; Andrea TESTA; Giles Albert BROWN; Martin AMBLER; Charlene FALLAN
- Web page: https://patentgrep.com/patent/US20260092061A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/499: Spiro-condensed pyrazines or piperazines
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- C07D 213/64: attached in position 2 or 6
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 471/10: Spiro-condensed systems
- C07D 487/08: Bridged systems
- C07D 487/10: Spiro-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- G01N 33/5038: {involving detection of metabolites per se}
- C40B 40/04: Libraries containing only organic compounds
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.

## Claims

### Claim 1

A bifunctional molecule comprising the general formula:
TBL-L-Z
wherein TBL is a target protein binding ligand that binds BRD9;
L is a linker; and
Z comprises a structure according to formula (I):
wherein
R1 is selected from C1 to C6 alkyl, benzyl, substituted benzyl, carbocyclyl, substituted carbocyclyl, heterocyclyl and substituted heterocyclyl, optionally wherein the C1 to C6 alkyl is substituted with one or more heteroatoms selected from halo, N, O and S and/or is substituted with a carbocyclic or heterocyclic group;
A is absent or is CR2R2′;
B is selected from aryl, heteroaryl, substituted aryl and substituted heteroaryl;
R2 and R2′ are each independently selected from H and C1 to C6 alkyl, optionally wherein the C1 to C6 alkyl is substituted with one or more heteroatoms selected from halo, N, O or S, or wherein R2 and R2′ together form a 3-, 4-, 5- or 6-membered carbocyclic or heterocyclic ring;
R3 is selected from C1-C6 alkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, substituted alkylcycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkyl heterocycloalkyl, substituted alkylheterocycloalkyl, aryl, substituted aryl, alkyl aryl, substituted alkylaryl, heteroaryl, substituted heteroaryl, alkyl heteroaryl, substituted alkylheteroaryl, optionally wherein the C1-C6 alkyl is substituted with one or more heteroatoms selected from halo, N, O and S;
R4 is H, C1 to C6 alkyl, optionally wherein the C1 to C6 alkyl is substituted with one or more heteroatoms selected from N, O or S;
or wherein R1 and R4 together form a 5-, 6-, or 7-membered heterocyclic ring;
or wherein when A is CR2R2′:
R1 and R2 together form a 5-, 6-, or 7-membered heterocyclic ring; or
R2 and R4 together form a 5-, 6-, or 7-membered heterocyclic or carbocyclic ring;
wherein L shows the point of attachment of the linker;
and
wherein the BRD9 binder (TBL) is of formula 1a:
wherein:
Z1 is N or CRA;
Z2 is N or CRB;
Z3 is N or CRD;
Z4 is N or CRE;
wherein no more than 3 of Z1, Z2, Z3 and Z4 are N;
RA and RE are each independently selected from the group consisting of —H, —O—C1-3alkyl and —C1-3alkyl;
RB and RD are each independently selected from the group consisting of —O—C1-3alkyl, —H, —OH, halogen, —NH2, —C1-3alkyl, —O—C1-3haloalkyl, —C1-3alkyl-O—C1-3alkyl, 4-7 membered heterocycloalkyl, —C1-3alkyl-SO2—C1-3alkyl, —C1-3alkyl-NH2, —C1-3alkyl-N(—C1-3alkyl)2, —N(C1-3 alkyl)2, —NH—RF;
RF is selected from —SO2—C1-3alkyl and —C1-3alkyl, wherein the —C1-3alkyl is optionally substituted with a 5 to 6 membered heteroaryl;
alternatively, RA and RB taken together form a benzene ring; alternatively, RC and Z2 or RC and Z3 taken together form a 5-7 membered heterocycloalkyl optionally substituted with —C1-3alkyl;
RC is selected from the group consisting of —H, —Y—RG, —NH2, —C1-3alkyl and 4-7 membered heterocycloalkyl;
Y is absent or is selected from the group consisting of —CRHRI—, —SO2— and —CO—;
RH and RI are each independently selected from —H or —C1-3alkyl; or RH and RI taken together form a —C3-4cycloalkyl,
RG is selected from the group consisting of —NH2, —OH, —C1-3alkyl, —N(RJRK), —O—RL, aryl, 5-6 membered heteroaryl, wherein the aryl and heteroaryl are optionally and independently substituted with one or more halogen, optionally substituted 4- to 7-membered monocyclic heterocycloalkyl, and optionally substituted 7- to 12-membered bicyclic heterocycloalkyl, which monocyclic or bicyclic heterocycloalkyl are optionally substituted with one or more groups independently selected from halogen, —OH, —NH2, —C1-3alkyl, —NHC1-3alkyl, —N(C1-3alkyl)2, —O—C1-3alkyl and —CH2—RM1;
RM1 is selected from 5-10 membered mono- or bicyclic aryl or heteroaryl, which is optionally substituted with —NH2, —OH, halogen, —CN, C1-3alkyl, —O—C1-3alkyl;
RJ is —H or —C1-3alkyl;
RK is selected from the group consisting of —C1-3alkyl, —C2-3alkyl-N(C1-3alkyl)2, —C2-3alkyl-NHC1-3alkyl, optionally substituted 4- to 7-membered monocyclic heterocycloalkyl, and optionally substituted 7- to 12-membered bicyclic heterocycloalkyl, which monocyclic or bicyclic heterocycloalkyl is optionally substituted with —C1-3alkyl;
RL is —C1-3alkyl or a 4-7 membered heterocycloalkyl, which heterocycloalkyl is optionally substituted with C1-3alkyl;
wherein when RC is Y—RG, RB and RD are each independently selected from —H, —OH, halogen, —NH2, —CN, —C1-3alkyl, —C1-3haloalkyl, —O—C1-3alkyl, —O—C1-3haloalkyl and —C1-3alkyl-O—C1-3alkyl; wherein at least one of the substituents RA to RE is not hydrogen;
and
A2 is selected from formulae 1b or 1c:
wherein the wavy fines intersect the bond between A2 and the carbon atom positioned ortho to RA and RE;
RM is selected from the group consisting of optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C1-6heteroalkyl, optionally substituted C3-10carbocyclyl, C2-6alkynyl and H;
Z5 is N or CRO;
Z is N or CRP;
Z7 is N or CRN;
wherein only one of Z5, Z6 and Z7 is N;
Z8 is CRW or N;
RN is selected from the group consisting of halogen, optionally substituted —C1-6alkyl, —H, C(O)C1-5alkyl, —NH2, optionally substituted amino, —OH, cyano, optionally substituted C1-6heteroalkyl, optionally substituted C3-10 carbocyclyl, optionally substituted C2-9heterocyclyl, optionally substituted C6-10aryl, optionally substituted C2-9heteroaryl, optionally substituted C2-6alkenyl, optionally substituted C2-6heteroalkenyl and thiol;
RO is selected from the group consisting of H, halogen, cyano, optionally substituted C1-6alkyl, optionally substituted C1-6heteroalkyl, optionally substituted C3-10carbocyclyl, optionally substituted C2-9heterocyclyl, optionally substituted C6-10aryl, optionally substituted C2-9heteroaryl, optionally substituted C2-6alkenyl, optionally substituted C2-6heteroalkenyl, hydroxy, thiol and optionally substituted amino;
RP is selected from the group consisting of H, halogen, optionally substituted C1-6alkyl, optionally substituted C1-6heteroalkyl, optionally substituted C3-10carbocyclyl and optionally substituted C6-10aryl;
alternatively, RN and Z5 taken together, combine to form an optionally substituted C6-10arene or optionally substituted C2-9heteroarene; optionally wherein RN and RO taken together with the carbon atoms to which they are joined, combine to form an optionally substituted C6-10arene or optionally substituted C2-9heteroarene;
RS is selected from the group consisting of H, optionally substituted C1-6alkyl, optionally substituted C1-6heteroalkyl and optionally substituted C3-10carbocyclyl;
RT is selected from the group consisting of H, optionally substituted C1-6alkyl, optionally substituted C1-6heteroalkyl, optionally substituted C3-10carbocyclyl, optionally substituted C2-9heterocyclyl, optionally substituted C6-10aryl, optionally substituted C2-9heteroaryl, optionally substituted C2-6alkenyl, optionally substituted C2-6heteroalkenyl, optionally substituted sulfone and optionally substituted sulfonamide, or RT and RU together with the atoms to which each is attached, form an optionally substituted C2-9heterocyclyl;
RU and RV are each independently selected from the group consisting of H, halogen, hydroxyl, optionally substituted C1-6alkyl, optionally substituted C1-6heteroalkyl, optionally substituted C3-10carbocyclyl, optionally substituted C2-9heterocyclyl, optionally substituted C6-10aryl, optionally substituted C2-9heteroaryl, optionally substituted C2-6alkenyl, optionally substituted C2-6heteroalkenyl, thiol, optionally substituted sulfone and optionally substituted amino;
alternatively, RT and RU together with the atoms to which each is attached, form an optionally substituted C2-9heterocyclyl;
RW is selected from the group consisting of H, halogen, optionally substituted C1-6alkyl, optionally substituted C1-6heteroalkyl, optionally substituted C3-10carbocyclyl, optionally substituted C2-9heterocyclyl, optionally substituted C6-10aryl and optionally substituted C2-9heteroaryl;
and
wherein the BRD9 binder is attached to the linker at any suitable position; and
(iii) wherein the bifunctional molecule is not:

### Claim 2 (depends on 1)

The bifunctional molecule of claim 1, wherein up to 1 of Z1, Z2, Z3 and Z4 is N.

### Claim 3 (depends on 1, 2)

The bifunctional molecule of claim 1 or claim 2, wherein the BRD9 binder is of formula 1a′:
wherein:
RA, RB, RC, RE, Z3 and A2 are as defined in claim 1 or 2.

### Claim 4 (depends on 1, 2, 3)

The bifunctional molecule of any one of claims 1 to 3, wherein A2 is selected from formula 1b′, wherein formula 1b′ is:
wherein the wavy line intersects the bond between A2 and the carbon atom positioned ortho to RA and RE;
RM is selected from the group consisting of —C1-5alkyl, -cyclopropyl, —C1-4haloalkyl and H;
RN is selected from the group consisting of halogen, —C1-5alkyl, —C1-3haloalkyl, —H, C(O)C1-5alkyl, —NH2, —NHC1-3alkyl and —OH;
Z5 is N or CRO
Z6 is N or CRP wherein only one of Z5 and Z6 may be N;
RO is H or —C1-3alkyl;
RP is H or —C1-3alkyl;
wherein only one of RO and RP may be —C1-3alkyl;
alternatively, RN and Z5 taken together form a benzene ring or a 5-6 membered heteroarene ring, each of which rings can be optionally and independently substituted with one or more groups selected from halogen, —OH, —NH2, —NH—C1-3alkyl and —C1-5alkyl, C1-5haloalkyl, C1-5alkoxy, C1-4haloalkoxy, 1d, C3-5azacycloalkyl, C2-5alkenyl, C2-5alkynyl, C3-5cycloalkyl, wherein the —C1-5alkyl group can be optionally substituted with 5-6 membered heteroaryl or phenyl;
wherein
Y2 is NRR or O;
Y1 is S(O)a or NRR;
each RR is independently H or C1-4alkyl;
each RQ is independently selected from the group consisting of C1-4alkyl, C1-4haloalkyl, halogen and —C(O)C1-3alkyl;
a is 0 to 2; and
r is 0 to 3.

### Claim 5 (depends on 1, 2, 3, 4)

The bifunctional molecule of any one of claims 1 to 4, wherein the BRD9 binder is of formula 1e, 1f or 1g:
wherein the wavy line intersects the bond between the BRD9 binder and the linker;
wherein RA, RB, RC, RE, RM, RN, Z3, Z5 and Z are as defined in any one of claims 1 to 4;
wherein RC′ is absent, or is as defined for RC in any one of claims 1 to 4;
ring 1A is a 5-7 membered heterocycloalkane optionally substituted with —C1-3alkyl; and
ring 1D is an optionally substituted C6-10aryl or optionally substituted C2-9heteroaryl.

### Claim 6 (depends on 5)

The bifunctional molecule of claim 5, wherein ring 1A:
(i) comprises one or two heteroatoms independently selected from the list consisting of N, S and O; or
(ii) is selected from the list consisting of pyrrolidine, piperidine, piperazine, morpholine, oxolane, oxane, tetrahydrothiophene and thiane.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The bifunctional molecule of any one of claims 1 to 5, wherein the BRD9 binder is of formula 1e, 1f′ or 1g′:
wherein the wavy line intersects the bond between the BRD9 binder and the linker; and
wherein RA, RB, RC, RE, RM, RN, Z3, Z5 and Z6 are as defined in any one of claims 1 to 4.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The bifunctional molecule of any one of claims 1 to 7, wherein RA, RB, RC, RD and REare independently selected from —O—C1-3alkyl, —H, halogen, —O—C1-3haloalkyl, —OH, —NH2, —C1-3alkyl, —C1-3alkyl-NH2, —C1-3alkyl-N(—C1-3alkyl)2 and —N(C1-3alkyl)2.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The bifunctional molecule of any one of claims 1 to 8, wherein:
(i) at least two of RA, RB, RD and RE are —H; and/or
(ii) at least one of RA, RB, RD and RE is selected from the group consisting of —O—C1-3alkyl, —H, halogen and —O—C1-3haloalkyl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The bifunctional molecule of any one of claims 1 to 9, wherein RM is —C1-5alkyl.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The bifunctional molecule of any one of claims 1 to 10, wherein RN is —C1-5alkyl or halogen, or RN and Z5 taken together form an optionally substituted 5-6 membered heteroarene or benzene ring, optionally wherein:
(i) the optionally substituted 5-6 membered heteroarene ring comprises one or more heteroatoms selected from the group consisting of N, S and O;
(ii) the optionally substituted 5-6 membered heteroarene ring is an N- or S-heteroarene; or
(iii) the optionally substituted 5-6 membered heteroarene ring is any one selected from the optionally substituted group consisting of pyridine, pyrrole, imidazole, pyrimidine, thiophene and pyrazole.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The bifunctional molecule of any one of claims 1 to 11, wherein the BRD9 binder is any one of formulae 1ea to 1eh and 1fa to 1ﬁ and 1ga:
wherein the wavy line intersects the bond between the BRD9 binder and the linker;
RA, RB, RE, RM, Z3 and Z8 are as defined in any one of claims 1 to 11;
RC is absent, or is as defined in any one of claims 1 to 11;
RN is selected from the group consisting of halogen, —C1-5alkyl, —C1-3haloalkyl, —H, C(O)C1-5alkyl, —NH2, —NHC1-3alkyl and —OH;
RO is H or —C1-3alkyl;
each RX is independently selected from the group consisting of halogen, —OH, —NH2, —NH—C1-3alkyl —C1-5alkyl, C1-5haloalkyl, C1-5alkoxy and C1-4haloalkoxy;
n is 0 to 3;
o is 0 to 2;
p is 0 or 1; and
q is 0 to 4.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The bifunctional molecule of any one of claims 1 to 12, wherein the BRD9 binder is according to formula 1ea′:
wherein the wavy line intersects the bond between the BRD9 binder and the linker;
RA and RE are each independently selected from H and —O—C1-3alkyl;
RB and RD are each independently selected from —O—C1-3alkyl, —H, -halo, —C1-3alkyl, and —O—C1-3haloalkyl;
RC is absent, or is —Y—RG;
Y is selected from the group consisting of —CRHRI—, and —CO—;
RH and RI are each independently selected from —H or —C1-3alkyl; or RH and RI taken together form a —C3-4cycloalkyl;
RG is selected from the group consisting of —N(RJRK)—, —N(C1-3alkyl)(optionally substituted 4- to 7-membered monocyclic heterocycloalkylene), or —N(C1-3alkyl)(optionally substituted 7- to 12-membered bicyclic heterocycloalkylene)); —O—;
optionally substituted 4- to 7-membered monocyclic heterocycloalkylene; and optionally substituted 7- to 12-membered heterocycloalkylene;
RJ and RKare as defined in claim 1;
RM is C1-3alkyl; and
RN, RO and RP are each independently selected from the group consisting of halo, —C1-3alkyl, and —C1-3haloalkyl.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The bifunctional molecule of any one of claims 1 to 12, wherein the BRD9 binder is an one of formulae 1h to 1z and 2a to 2g:
wherein RC is absent, or is —Y—RG;
Y is selected from the group consisting of —CRHRI—, and —CO—;
RH and RI are each —H; or RH and RI taken together form a —C3-4cycloalkyl;
RG is selected from the group consisting of —N(RJRK), N(C1-3alkyl)(optionally substituted 4- to 7-membered monocyclic heterocycloalkylene), or —N(C1-3alkyl)(optionally substituted 7- to 12-membered bicyclic heterocycloalkylene)); —O—; optionally substituted 4- to 7-membered monocyclic heterocycloalkylene containing one or two N ring atoms;
and optionally substituted 7- to 12-membered bicyclic heterocycloalkylene containing one or two N ring atoms;
RJ and RKare as defined in claim 1;
wherein the wavy line intersects the bond between the BRD9 binder and the linker.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A bifunctional molecule according to any one of claims 1 to 14, wherein RC is present and is any one selected from:
wherein Y is CRHRI;
RG1 and RG2 are each independently selected from H and C1-C3 alkyl;
RJ is as defined in claim 1; and
L shows the point of attachment of the linker.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A bifunctional molecule according to any one of claims 1 to 15, wherein:
(i) when R1 and R4 together form a 5-, 6-, or 7-membered heterocyclic ring, Z is represented by formula (Ia):
wherein A, B, R3 and L are as defined for formula (I); and
n is 1, 2 or 3;
W is selected from CRW1RW2, O, NRW3 and S;
RW1, RW2 and RW3 are each independently selected from H and C1 to C6 alkyl; and wherein when n is 2 or 3, each W is independently selected from CRW1RW2, O, NRW3, and S;
(ii) when R1 and R2 together form a 5-, 6-, or 7-membered heterocyclic ring, Z is represented as formula (Ib):
Wherein B, R2′, R3, R4 and L are as defined for formula (I);
m is 3, 4 or 5;
each T is independently selected from CRT1RT2, O, NRT3 and S; and
RT1, RT2 and RT3 are each independently selected from H and C1 to C6 alkyl; or
(iii) when R2 and R4 together form a 5-, 8-, or 7-membered heterocyclic or carbocyclic ring, Z is represented as formula (Ic):
Wherein B, R1, R2′, R3 and L are as defined for formula (I);
p is 2, 3 or 4; and
each U is independently selected from CRU1RU2, O, NRU3 and S; and
RU1, RU2 and RU3 are each independently selected from H and C1 to C6 alkyl.

### Claim 17

The bifunctional molecule according to any one of the preceding claims, wherein R3 is selected from the group consisting of a heteroaryl, substituted heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloheteroalkyl, C1-C6 alkyl substituted with a heterocyclic group, aryl, and substituted aryl,
optionally wherein R3 is selected from:
wherein the dotted line indicates the position at which each of the respective R3 groups is joined to the structure shown in formula (I) to (Ic), or wherein when the dotted line is not appended to an atom, the dotted line indicates that each of the respective R3 groups is joined to the structure via any position on the aromatic or heteroaromatic ring;
each R5 is independently selected from the group consisting of halo, CH2OH, CF3, —CH2F, —CHF2, OCF3, —OCH2F, —OCHF2, C1 to C6 alkyl, —CN, —OH, —OMe, —SMe, —SOMe, —SO2Me, —NH2, —NHMe, —NMe2, CO2Me, —NO2, CHO and COMe;
n is 0 to 3;
R6 is C1 to C6 alkyl;
G is CH2, O and NH; and
Q is C1 to C6 alkylene.

### Claim 18

The bifunctional molecule according to any one of the preceding claims, wherein A is CR2R2′, optionally wherein: (i) one of R2 and R2′ is a hydrogen and the other is C1 to C6 alkyl, optionally wherein the C1 to C6 alkyl is substituted with one or more halo atoms; or (ii) both of R2 and R2′ are selected from C1 to C6 alkyl.

### Claim 19

The bifunctional molecule according to any one of the preceding claims, wherein Z is represented as formula (IIaa):
wherein A, R3, and L are as defined for formula (I);
n is 1, 2 or 3; and
W is selected from CRW1RW2, O, NRW3 and S; and
RW1, RW2 and RW3 are each independently selected from H and C1 to C6 alkyl; and
wherein when n is 2 or 3, each W is independently selected from CRW1RW2, O, NRW3, and S;
optionally wherein:
(i) Z is represented as formula (IIa):
wherein R2, R2′, R3 and L are as defined in any one of the preceding claims,
n is 1, 2 or 3; and
W is selected from CRW1RW2, O, NRW3 and S; and
RW1, RW2 and RW3 are each independently selected from H and C1 to C6 alkyl; and
wherein when n is 2 or 3, each W is independently selected from CRW1RW2, O, NRW3, and S.

### Claim 20

The bifunctional molecule according to any one of the preceding claims, wherein the linker comprises 1 to 25 or 1 to 18 atoms in a single linear chain.

### Claim 21

The bifunctional molecule according to any one of the preceding claims, wherein linker comprises 1 to 10 or 1 to 8 rotatable bonds.

### Claim 22

The bifunctional molecule according to any one of the preceding claims, wherein the linker (L) is a covalent bond or the structure of the linker (L) is:
(Lx)q
wherein each Lx represents a subunit of L that is independently selected from CRL1RL2, O, C═O, S, SO, SO2, NRL3, SONRL4, SONRL5C═O, CONRL6, NRL7CO, C(RL8)═C(RL9), C≡C, aryl, substituted aryl, heteroaryl, substituted heteroaryl, carbocyclyl, substituted carbocyclyl, heterocyclyl and substituted heterocyclyl groups;
wherein RL1, RL2, RL3, RL4, RL5, RL6, RL7, RL8 and RL9 are each independently selected from H, halo, C1 to C6 alkyl, C1 to C6, haloalkyl, —OH, —O(C1 to C6 alkyl), —NH2, —NH(C1 to C6 alkyl), —NO2, —CN, —CONH2, —CONH(C1 to C6 alkyl), —CON(C1 to C6 alkyl)2, —SO2(C1 to C6 alkyl), —CO2(C1 to C6 alkyl), and —CO(C1 to C6 alkyl); and
q is an integer between 1 and 30.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The bifunctional molecule according to any one of claims 1 to 22, wherein the linker (L) may be represented as shown in formula (Lia):
wherein L1A is absent or is selected from C1-C6 alkylene, C1-C6 alkoxy and C1-C6 alkylamino;
L2A is —NRL2AC═O— or —C═ONRL2A—; and
L3A is selected from C1-C3 alkylene, C1-C6 alkoxy and C1-C6 alkylamino;
wherein RL2A is H or C1-C6 alkyl);
or, the structure of the linker L may be represented as shown in formula (L1b):
wherein L1B is absent or is selected from C1-C3 alkylene, C1-C6 alkoxy and C1-C6 alkylamino;
L2B is —NRL2AC═O— or —C═ONRL2A—;
L3B is selected from C1-C15 alkylene, —[(CH2)2O]1-6(CH2)2—;
L4B is —NRL2AC═O— or —C═ONRL2A— wherein RL2A is H or C1-C6 alkyl;
L5B is selected from C1-C3alkylene, C1-C6 alkoxy and C1-C6 alkylamino;
wherein RL2A is H or C1-C6 alkyl);
or, the structure of the linker (L) may be represented as shown in formula (L1c):
wherein L1C is an optionally substituted 4- to 7-membered monocyclic N-heterocycloalkyl, an optionally substituted 7- to 12-membered bicyclic N-heterocycloalkyl, or an optionally substituted 8- to 18-membered tricyclic N-heterocycloalkyl, each optionally containing one or two additional ring heteroatoms selected from N, O and S;
L2C is absent or is selected from C1-C3 alkylene, C1-C6 alkoxy and C1-C6 alkylamino;
L3C is —RL2BC═O— or —(C═O)RL2B—; and
L4C is selected from C1-C3alkylene, C1-C6 alkoxy and C1-C6 alkylamino;
wherein:
RL2A is H or C1-C6 alkyl; and
RL2B is NRL2A; or an N-linked optionally substituted 4- to 7-membered monocyclic N-heterocycloalkyl, an optionally substituted 7- to 12-membered bicyclic N-heterocycloalkyl, or an optionally substituted 8- to 18-membered tricyclic N-heterocycloalkyl, each optionally containing one or two additional ring heteroatoms selected from N, O and S;
or, the structure of the linker (L) may be represented as shown in formula (L1d):
wherein L1D is absent or is selected from C1-C3 alkylene, CO, C1-C3 alkylene(N(C1-C3 alkyl);
L2D is NRL2A or an optionally substituted 4- to 7-membered monocyclic N-heterocycloalkyl, an optionally substituted 7- to 12-membered bicyclic N-heterocycloalkyl, or an optionally substituted 8- to 18-membered tricyclic N-heterocycloalkyl, each optionally containing one or two additional ring heteroatoms selected from N, O and S; wherein RL2A is H or C1-C6 alkyl; and
L3D is absent or is selected from C1-C3 alkylene, —O—, —N(C1-C3 alkyl)-, and CO;
or, the structure of the linker (L) may be represented as shown in formula (L1e):
wherein L1E is C1-C3 alkylene or CO;
L2E is an optionally substituted 4- to 7-membered monocyclic N-heterocycloalkyl, an optionally substituted 7- to 12-membered bicyclic N-heterocycloalkyl, each optionally containing one or two additional ring heteroatoms selected from N, O and S; and
L3E is selected from C1-C3 alkylene;
or, the linker (L) may be represented as shown in formula (L1f):
L1F (L1f)
wherein L1F is selected from C1-C3 alkylene, CO, and C1-C3 alkylene(NRL1C); wherein
RL1C is H or C1-C3 alkyl.

### Claim 24

The bifunctional molecule according to any one of the preceding claims, wherein the bifunctional molecule has a structure as shown in Table 1.

### Claim 25

A pharmaceutical composition comprising the bifunctional molecule according to any one of the preceding claims, together with a pharmaceutically acceptable carrier, optionally wherein the bifunctional molecule is present in the composition as a pharmaceutically acceptable salt, solvate or derivative.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The bifunctional molecule according to any one of claims 1 to 24 or the pharmaceutical composition of claim 25, for use in medicine.

### Claim 27 (depends on 26)

The bifunctional molecule or pharmaceutical composition for use of claim 26, wherein the use comprises the treatment and/or prevention of any disease or condition which is associated with and/or is caused by an abnormal level of BRD9 activity.

### Claim 28 (depends on 26, 27)

The bifunctional molecule or pharmaceutical composition for use of claim 26 or 27, wherein the disease or condition is cancer.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of selectively degrading and/or increasing proteolysis of BRD9 in a cell, the method comprising contacting and/or treating the cell with a bifunctional molecule as defined in any one of claims 1 to 24 or a pharmaceutical composition as defined in claim 25.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of making a bifunctional molecule as defined in any one of claims 1 to 24.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of screening the bifunctional molecules according to any one of claims 1 to 24, comprising:
a. providing a bifunctional molecule comprising:
(i) a first ligand comprising a structure according to Z as defined in any one of claims 1 and 16 to 19;
(ii) a second ligand that binds to BRD9 as defined in any one of claims 1 to 15; and
(iii) a linker that covalently attaches the first and second ligands as defined in any one of claims 1 and 20 to 23;
b. contacting a cell with the bifunctional molecule;
c. detecting degradation of BRD9 in the cell;
d. detecting degradation of BRD9 in the cell in the absence of the bifunctional molecule; and
e. comparing the level of degradation of BRD9 in the cell contacted with the bifunctional molecule to the level of degradation of BRD9 in the absence of the bifunctional molecule;
wherein an increased level of degradation of BRD9 in the cell contacted with the bifunctional molecule indicates that the bifunctional molecule has facilitated and/or promoted the degradation of BRD9,
optionally wherein detecting degradation of BRD9 comprises detecting changes in the levels of the target protein in the cell.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A compound library comprising a plurality of bifunctional molecules according to any one of claims 1 to 24.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A compound library comprising a plurality of TBL or L or Z portions of bifunctional molecules according to any one of claims 1 to 24.
